Razavi International Journal of Medicine

Published by: Kowsar

Vitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial

Hasan Vosoghinia 1 , Abbas Esmaeilzadeh 1 , Azita Ganji 1 , Seyed Mousal-Reza Hosseini 1 , Saeid Amel Jamehdar 2 , Maryam Salehi 3 , Ali Bahari 1 , Omid Ghanaei 1 , Maryam Sahebari 4 , Farnood Rajabzadeh 5 , Kamran Ghaffarzadehgan 6 and Ladan Goshayeshi 1 , *
Authors Information
1 Department of Gastroenterology and Hepatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
3 Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
4 Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
5 Department of Radiology, School of Medicine, Mashhad Branch, Islamic Azad University, Mashhad, IR Iran
6 Department of Pathology, Research and Education Department, Razavi Hospital, Mashhad, IR Iran
Article information
  • Razavi International Journal of Medicine: June 30, 2016, 4 (2); e36632
  • Published Online: May 21, 2016
  • Article Type: Research Article
  • Received: January 27, 2016
  • Revised: April 5, 2016
  • Accepted: April 28, 2016
  • DOI: 10.17795/rijm36632

To Cite: Vosoghinia H, Esmaeilzadeh A, Ganji A, Hosseini S M, Jamehdar S A, et al. Vitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial, Razavi Int J Med. 2016 ; 4(2):e36632. doi: 10.17795/rijm36632.

Abstract
Copyright © 2016, Razavi Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Neal KR, Trent Hepatitis CG, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut. 2007; 56(8): 1098-104[DOI][PubMed]
  • 2. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, et al. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med. 2010; 13(4): 306-12[PubMed]
  • 3. Khodabandehloo M, Roshani D. Prevalence of hepatitis C virus genotypes in Iranian patients: a systematic review and meta-analysis. Hepat Mon. 2014; 14(12)[DOI][PubMed]
  • 4. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010; 14 Suppl 3-6[DOI][PubMed]
  • 5. Kermani FR, Sharifi Z, Ferdowsian F, Paz Z, Zamanian M. Distribution of hepatitis c virus genotypes among chronic infected injecting drug users in Tehran, Iran. Jundishapur J Microbiol. 2013; 6(3): 265-8
  • 6. Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009; 86(6): 902-8[DOI][PubMed]
  • 7. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014; 384(9941): 414-26[DOI][PubMed]
  • 8. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 9. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol. 2007; 22(6): 832-6[DOI][PubMed]
  • 10. Chopp S, Vanderwall R, Hult A, Klepser M. Simeprevir and sofosbuvir for treatment of hepatitis C infection. Am J Health Syst Pharm. 2015; 72(17): 1445-55[DOI][PubMed]
  • 11. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol. 2012; 18(8): 800-5[DOI][PubMed]
  • 12. Watkins RR, Lemonovich TL, Salata RA. An update on the association of vitamin D deficiency with common infectious diseases. Can J Physiol Pharmacol. 2015; 93(5): 363-8[DOI][PubMed]
  • 13. Iruzubieta P, Teran A, Crespo J, Fabrega E. Vitamin D deficiency in chronic liver disease. World J Hepatol. 2014; 6(12): 901-15[DOI][PubMed]
  • 14. Van Belle TL, Gysemans C, Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases: a vital player? Best Pract Res Clin Endocrinol Metab. 2011; 25(4): 617-32[DOI][PubMed]
  • 15. Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, et al. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother. 2007; 51(6): 2016-27[DOI][PubMed]
  • 16. Matsumura T, Kato T, Sugiyama N, Tasaka-Fujita M, Murayama A, Masaki T, et al. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology. 2012; 56(4): 1231-9[DOI][PubMed]
  • 17. Petta S, Ferraro D, Camma C, Cabibi D, Di Cristina A, Di Marco V, et al. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther. 2012; 17(5): 823-31[DOI][PubMed]
  • 18. Luo YQ, Wu XX, Ling ZX, Cheng YW, Yuan L, Xiang C. Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis. J Zhejiang Univ Sci B. 2014; 15(10): 900-6[DOI][PubMed]
  • 19. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol. 2011; 17(47): 5184-90[DOI][PubMed]
  • 20. Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat. 2014; 21(5): 348-56[DOI][PubMed]
  • 21. Esmat G, El Raziky M, Elsharkawy A, Sabry D, Hassany M, Ahmed A, et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res. 2015; 35(1): 49-54[DOI][PubMed]
  • 22. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010; 55(9): 2624-8[DOI][PubMed]
  • 23. Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc. 2010; 85(8): 752-7[DOI][PubMed]
  • 24. Terrier B, Lapidus N, Pol S, Serfaty L, Ratziu V, Asselah T, et al. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World J Gastroenterol. 2015; 21(18): 5647-53[DOI][PubMed]
  • 25. Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J Hepatol. 2014; 61(6): 1247-52[DOI][PubMed]
  • 26. Berak H, Laskus T, Kolakowska-Rzadzka A, Wasilewski M, Stanczak JJ, Bardadin K, et al. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study. Adv Med Sci. 2014; 59(2): 261-5[DOI][PubMed]
  • 27. Alavian SM, Ahmadzad M, Keshvari M. Efficacy and safety of interferon-alpha (PDferon B) and ribavirin combination therapy in patients with chronic hepatitis C in Iran. Hepat Mon. 2006; 6: 11-8
  • 28. Chen EQ, Shi Y, Tang H. New insight of vitamin D in chronic liver diseases. Hepatobiliary Pancreat Dis Int. 2014; 13(6): 580-5[PubMed]
  • 29. Jimenez-Sousa MA, Rallon N, Berenguer J, Pineda-Tenor D, Lopez JC, Soriano V, et al. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients. J Clin Virol. 2015; 65: 62-7[DOI][PubMed]
  • 30. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004; 80(6 Suppl): 1689S-96S[PubMed]
  • 31. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005; 289(1)-28[DOI][PubMed]
  • 32. Muller K, Bendtzen K. 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Investig Dermatol Symp Proc. 1996; 1(1): 68-71[PubMed]
  • 33. Hewison M. Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol. 2010; 321(2): 103-11[DOI][PubMed]
  • 34. Trochoutsou AI, Kloukina V, Samitas K, Xanthou G. Vitamin-D in the Immune System: Genomic and Non-Genomic Actions. Mini Rev Med Chem. 2015; 15(11): 953-63[PubMed]
  • 35. Sabry D, Al-Ghussein MA, Hamdy G, Abul-Fotouh A, Motawi T, El Kazaz AY, et al. Effect of vitamin D therapy on interleukin-6, visfatin, and hyaluronic acid levels in chronic hepatitis C Egyptian patients. Ther Clin Risk Manag. 2015; 11: 279-88[DOI][PubMed]
  • 36. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology. 2011; 53(4): 1118-26[DOI][PubMed]
  • 37. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology. 2010; 51(4): 1158-67[DOI][PubMed]
  • 38. Lange CM, Gouttenoire J, Duong FH, Morikawa K, Heim MH, Moradpour D. Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to IFN-alpha. J Immunol. 2014; 192(12): 6037-44[DOI][PubMed]
  • 39. Duan X, Guan Y, Li Y, Chen S, Li S, Chen L. Vitamin D Potentiates the Inhibitory Effect of MicroRNA-130a in Hepatitis C Virus Replication Independent of Type I Interferon Signaling Pathway. Mediators Inflamm. 2015; 2015: 508989[DOI][PubMed]
  • 40. Alipour S, Saberi A, Seifollahi A, Shirzad N, Hosseini L. Risk factors and prevalence of vitamin d deficiency among Iranian women attending two university hospitals. Iran Red Crescent Med J. 2014; 16(10)[DOI][PubMed]
  • 41. Heshmat R, Mohammad K, Majdzadeh SR, Forouzanfar MH, Bahrami A, Omrani GHR. Vitamin D deficiency in Iran: A multi-center study among different urban areas. Iran J Public Health. 2008; 37
  • 42. Pinzone MR, Di Rosa M, Malaguarnera M, Madeddu G, Foca E, Ceccarelli G, et al. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci. 2013; 17(9): 1218-32[PubMed]
  • 43. Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology. 2012; 56(1): 49-56[DOI][PubMed]
  • 44. Lambert AA, Drummond MB, Mehta SH, Brown TT, Lucas GM, Kirk GD, et al. Risk factors for vitamin D deficiency among HIV-infected and uninfected injection drug users. PLoS One. 2014; 9(4)[DOI][PubMed]
  • 45. Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, et al. Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. PLoS One. 2014; 9(2)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments